Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of Perifosine (YHI-1003) plus capecitabine in refractory advanced colorectal cancer
jRCT2080221670Phase 2
- Sponsor
- Yakult Honsha
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perifosine in colorectal cancer (CRC), sponsored by Yakult Honsha.
02
Drugs
perifosine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080221670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221670.